NCT06490913

Chemotherapy Plus EGFR Monoclonal Antibody in Patients With Liver Metastases From Colorectal Cancer With ctDNA Superselective Negative Genes

Chemotherapy Plus EGFR Monoclonal Antibody in Patients With Liver Metastases From Colorectal Cancer With ctDNA Superselective Negative Genes：a Phase II Single-arm Study

• Status: Not Yet Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 33 (estimated)
• Sponsor: Fujian Cancer Hospital · Other Government
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this Phase II single-arm study is to prospectively explore the efficacy of chemotherapy plus EGFR inhibitors in patients with liver metastases from total wild-type colorectal cancer with ctDNA superselective negative genes.

Conditions

• Liver Metastases of Colorectal Cancer

Interventions

Type	Name	Description
DRUG	Capecitabine	1000mg/m2, bid, d1-d14，q3w，1cycle
DRUG	oxaliplatin	130mg/m2, ivgtt, d1，q3w，1cycle
DRUG	Cetuximab	cetuximab 500mg/m2, q2w
DRUG	Oxaliplatin	85mg/m2, d1,q2w
DRUG	Leucovorin	400mg/m2, d1,q2w
DRUG	5-FU	400mg/m2，d1,q2w

Timeline

• Start date: 2024-11-01
• Primary completion: 2025-06-30
• Completion: 2025-12-31
• First posted: 2024-07-08
• Last updated: 2024-07-08